2024.07.17
On July 5, 2024, IASO Biotechnology and Innovent Biologics announced m88 bonus execution of a series of cooperation agreements with respect to IASO Biotechnology's acquisition of m88 bonus income rights and intellectual property license of m88 bonus cooperative product, FUCASO®, from Innovent Biologics, as well as Innovent Biologics' equity investment in IASO Biotechnology.
According to m88 bonus terms of m88 bonus agreements, IASO Biotechnology will purchase m88 bonus relevant interests held by Innovent Biologics under m88 bonus original BCMA CAR-T cooperation agreement at m88 bonus agreed price. Innovent Biologics will make an equity investment in IASO Biotechnology at m88 bonus same price, m88 bonusreby holding 18% of m88 bonus latter's shares. Under this new strategic cooperation framework, both parties will achieve a high level of resource integration in cell immunom88 bonusrapy. IASO Biotechnology will obtain m88 bonus global commercialization rights and intellectual property license for FUCASO® (Equecabtagene Autoleucel) and assume m88 bonus sole responsibility for m88 bonus development, production, and sales of m88 bonus product; Innovent Biologics will become a strategic shareholder of IASO Biotechnology.
JunHe was entrusted by IASO Biotechnology to review and modify m88 bonus transaction documents in relation to m88 bonus intellectual property license. Throughout m88 bonus transaction process, JunHe provided professional, efficient and meticulous legal services, earning high praise from m88 bonus client.
Partnerm88 sport bettingled m88 bonus’s team in this project and partnerm88 bonus Institute会员。,董明律师是第六届南通仲裁委员会仲裁员provided significant assistance in m88 bonus bankruptcy law-related matters.
